Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis
Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions
Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes
Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection
Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients
Objective: To establish a registry of PD patients in Thailand treated with subcutaneous apomorphine (APO) injection or infusion to allow prospective data collection from the…The Effects of Apomorphine infusion on Head ptosis, a case report
Objective: Sustained Effects of Apomorphine infusion on Head Ptosis, a case report Background: IntroductionHead ptosis (Hp) results from weakness of the neck extensor, or increased…Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017
Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine
Objective: To evaluate the efficacy of 4 treatment modalities on apomorphine-induced subcutaneous nodules as compared to no treatment. Background: Subcutaneous nodules are the most common adverse events…Apomorphine induced hemolytic anemia: A case report and literature review
Objective: To present a case of apomorphine induced hemolytic anemia Background: Drug induced immune hemolytic anemia (DIIHA) is a potentially lethal adverse reaction; It has…Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes
Objective: Exposure-response models were developed to characterize the relationship between apomorphine exposure and (1) efficacy using Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »